@article {CampbellP03.201作者={乔纳森·坎贝尔和Vahram Ghushchyan r·布雷特•麦奎因和Sharon Cahoon-Metzger Terrie利文斯通盖Vollmer和约翰Corboy奥古斯托Miravalle,泰瑞称与Nair}, title ={直接成本、间接成本和质量的生活负担的多发性硬化症:国家我们估计(P03.201)},体积={80},数量={7}补充,页面= {P03.201——P03.201} ={2013},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:进行全面的评估当前的经济和健康相关生命质量(HRQoL)负担的多发性硬化症(MS)在美国使用医疗费用委员会全国代表性数据调查(议员)。首页背景:女士对重要但不是well-quantified负担的病人,他们的家庭/照顾者,雇主,和医疗保健系统。设计/方法:我们发现了一个样本的非制度化患者年龄> = 18岁女士(ICD-9代码340)使用议员数据(1998 - 2009)和比较它们对个人没有在面试的女士。组比较:医疗利用率及其相关(直接)成本,间接成本(包括就业状况和工作日错过),和HRQoL包括质量调整生命年(提升)。由于测量议员的局限性,我们不能包括所有疾病修饰治疗(DMT)利用和相关的成本。分析建模使用负二项,普通最小二乘,和逻辑回归,调整人口和临床特点。结果:年度流行女士估计为572312 (95 \ % CI: 397004、747619)。年度直接医疗支出11065美元高女士与非MS (95 \ % CI: 8888美元,13242美元)。年度成本组件高女士与非MS包括:门诊访问3443美元(95 \ % CI 2442美元,4445美元),处方(不含DMT)花费1834美元(95 \ % CI 1242美元,2427美元),和住院住院1546美元(95 \ % CI 39美元,3054美元)。医学患者的3.3倍(95 \ % CI: 2.4, 4.5)的几率增加失业和高4.4倍的天数在床上(CI 95 \ % 2.97, 6.45)和非MS。女士一生平均qaly失去了10.04而非MS。结论:研究结果证实,医学患者有较高的医疗费用和利用率比非MS同行,并面临高失业率和生活质量下降。 Prevalence of MS is likely higher than previous conservative US estimates but may still be underestimated in this analysis due to the non-institutionalized study population.Supported by: Biogen Idec.Disclosure: Dr. Campbell has received personal compensation for activities with PEcon LLC. Dr. Campbell has received research support from Amgen Inc, Biogen Idec, and Novartis. Dr. Ghushchyan has received personal compensation for activities with Janssen Pharmaceuticals Inc and Biogen Idec as a consultant. Dr. Ghushchyan has received research support from Janssen Pharmaceuticals Inc and Biogen Idec. Dr. McQueen has received personal compensation for activities with Veritech Corporation as a consultant. Dr. Cahoon-Metzger has received personal compensation for activities with Biogen Idec. Dr. Cahoon-Metzger holds stock and/or stock options in Biogen Idec, which sponsored research in which Dr. Cahoon-Metzger was involved as an investigator. Ms. Livingstone has received personal compensation for activities with Biogen Idec. Ms. Livingstone holds stock and/or stock options in Biogen Idec. Dr. Vollmer has received personal compensation for activities with Genzyme Corporation, Acorda Therapeutics, Accelerated Cure Projects for MS, Bristol-Myers Squibb Company, Teva Neuroscience, Biogen Idec, Novartis, and Hoffman-LaRoche. Dr. Vollmer has received research support from Teva Neuroscience, Genzyme Corporation, Ono Pharmaceutical, Biogen Idec, Janssen, and the National Institutes of Health. Dr. Corboy has received personal compensation for activities with ProCE, Celgene Therapeutics, Teva Neuroscience, and Novartis. Dr. Corboy has received personal compensation in an editorial capacity for Neurology Clinical Practice. Dr. Miravalle has received personal compensation for activities with Bayer Healthcare Pharmaceuticals Inc, Biogen Idec, Questcor Pharmacueticals, Inc; EMD Serono, and Teva Neuroscience. Dr. Schreiner has received personal compensation for activities with Teva Neurosciences as lecturer. Dr. Nair has received personal compensation for activities with Centecor, Janssen, and Biogen Idec. Dr. Nair has received research support from Centecor, Janssen, and Biogen Idec.Tuesday, March 19 2013, 2:00 pm-6:30 pm}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/80/7_Supplement/P03.201}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }